The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to offer a more substantial loss in bod